Tyra Biosciences(TYRA) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3 million at Q2 2025; runway through at least 2027 - • Dabogratinib (formerly TYRA-300) is an oral investigational FGFR3-selective inhibitor being developed for the treatment of IR NMIBC and ACH. o Dosed first patient in Phase 2 NMIBC Study – SURF302. SURF30 ...